Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Myriad Genetics, Inc.    MYGN

Analysis summary4-Traders Strategies 

Near a solid support area

share with twitter share with LinkedIn share with facebook
share via e-mail
02/19/2013 | 03:00pm
Opinion : Bullish above USD 24.2
Target price : USD 26.1
Stop loss: USD 23.6
Advanced Medical Equipment & Technology

Myriad Genetics' share price was heavily penalized and is now in an oversold situation near to a solid support area.

Myriad Genetics is technically oversold and is near to the USD 24.2 support. This situation gives credit to a potential technical rebound. Thus, the stock could find new energy and would rise towards the next USD 26.1 resistance.

So as to make the most of a potential technical rebound of Myriad Genetics, it seems opportune to take a long position at the current price. A confirmation of this pattern would enable the security to reach the USD 27.62 resistance, with a potential gain of 13.2 %. Investors should not insist under USD 24.19 and place a stop loss order under this threshold.

Myriad Genetics, Inc. : Near a solid support area

© Zonebourse.com 2013
share with twitter share with LinkedIn share with facebook
share via e-mail

Disclaimer: 4-traders.com is a website published by SURPERFORMANCE SAS. Surperformance or 4-traders.com is not a registered broker-dealer nor a registered investment adviser. You understand that this web site and its content is furnished for your personal, noncommercial, informational purposes only, and that no mention of a particular security in this website constitutes a recommendation to buy, sell, or hold any other security, nor that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person. Surperformance and 4-traders.com services will not advise you personally concerning the nature, potential, value or suitability of any particular security, portfolio of securities, transaction, investment strategy or other matter. Information regarding trading and investment as provided by Surperformance professional is not tailored to the investment needs of any specific person. You acknowledge that you are responsible for your own financial decisions and should seek a registered financial agent depending on your own risk tolerance to advise you on your personal trading activities.

Develops therapeutic and predictive medicine productsMyriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic test.It operates through the following segments: Research, Molecular Diagnostics, and Companion Diagnostics.The Research segment is... 
Advanced Medical Equipment & Technology
06/05 | 03:00pmPresentation
More about the company
Financials ($)
Sales 2017 765 M
EBIT 2017 83,4 M
Net income 2017 38,4 M
Debt 2017 26,0 M
Yield 2017 -
P/E ratio 2017 42,61
P/E ratio 2018 31,30
EV / Sales 2017 1,83x
EV / Sales 2018 1,63x
Capitalization 1 377 M
More Financials
Duration : Period : Day
Myriad Genetics, Inc. Technical Analysis Chart | MYGN | US62855J1043 | 4-Traders
Duration : Period : Week
Myriad Genetics, Inc. Technical Analysis Chart | MYGN | US62855J1043 | 4-Traders
Surperformance© ratings  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Earnings quality
Business Predictability
P/E ratio
Yield -
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
Bollinger Spread
Unusual Volumes
More Ratings